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To the Editor 
In the context of COVID-19, a wide range of serology immunoassays with different SARS-
CoV-2 antigen recognition and antibody specificity have been developed to complement RT-
PCR assays [1]. Serological testing is useful for diagnosis and characterization of the course of 
the disease, identification of convalescent plasma donors, for epidemiology studies, lockdown 
exit programs and COVID-19 vaccine development [2, 3]. Due to the widespread dissemination 
of these new methods and the limited experience with these assays, it is crucial for laboratories 
to rigorously validate these methods before broad introduction into routine clinical practice. 
Independent validations are also needed to assure the assays are in line with expected analytical 
and clinical performance specifications [1-4].  
This study is the first to report the external validation of a new electrochemiluminescent 
immunoassay (ECLIA) test, the Elecsys anti-SARS-CoV-2 from Roche Diagnostics®. This test 
allows the detection of total antibodies (including IgG) specifically directed against SARS-
CoV-2 nucleocapsid and is performed on the cobas® e801 module. The test result is given as a 
cut-off index (COI). According to the manufacturer, a result <1.0 is considered negative while 
a result ≥1.0 is considered positive [5]. The within-run and between-run imprecision (CV) on 
5 patient pools (COI means of 0.081, 1.0, 8.7, 24, and 54) varied from 0.8% to 3.3%, and from 
1.2% to 3.6%, respectively. Sample storage complied with the conditions listed in the package 
insert. 
This retrospective study was conducted from May 6 to 12, 2020 at the clinical biology 
laboratory of the Clinique Saint-Luc Bouge (SLBO, Namur, Belgium). Serum samples (n=140) 
obtained from 97 patients with a confirmed RT-PCR SARS-CoV-2 diagnosis were used to 
determine the clinical sensitivity of the assay. RT-PCR on respiratory samples (nasopharyngeal 
swab samples) was performed on the LightCycler® 480 Instrument II using the LightMix® 
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different categories based on the number of days after a positive RT-PCR test as follows: 0-6 
days: 45 sera; 7-13 days: 35 sera; 14-20 days: 24 sera; 21-27 days: 15 sera; 28 days or more: 
21 sera. Among the 60 samples collected 14 or more days after the RT-PCR positive detection, 
and using the manufacturer’s cut-off, the Elecsys anti-SARS-CoV-2 immunoassay identified 
55 true positive and 5 false negative samples. The diagnostic sensitivity was 91.7% (95%CI: 
81.6-97.2%). Using the optimal cut-off provided by ROC curve analyses (i.e.>0.165) improved 
the performance of the test to give a sensitivity of 100% (95%CI: 94.0-100%) (Figure 1). 
A sensitivity analysis was also performed considering the date of symptom onset. Among the 
97 patients, data about time of symptom onset were available for 92 patients. The collected 
samples (n=129) were subdivided into different categories according to the number of days 
after the onset of symptoms as follows: 0-6 days: 22 sera; 7-13 days: 28 sera; 14-20 days: 26 
sera; 21-27 days: 23 sera; 28 days or more: 30 sera. Among the 79 samples evaluated 14 or 
more days after the onset of symptoms, and using the manufacturer’s cut-off, the Elecsys anti-
SARS-CoV-2 assay identified 72 true positive and 7 false negative samples. The diagnostic 
sensitivity was 91.1% (95%CI: 82.6-96.4%). Using the ROC curve cut-off (i.e.>0.165) 
improved the performance of the tests with a sensitivity of 95.1% (95%CI: 88.0-98.7%). 
Analyses of serum samples obtained 28 days or more after symptom onset provided a sensitivity 
of 96.7% (95%CI: 82.8-99.9%) and 100% (95%CI: 88.9-100%) with the manufacturer and the 
optimized cut-off, respectively (Figure 1). 
Considering samples obtained before 14 days (from RT-PCR + or symptoms onset), 
sensitivities were not sufficient to be reliable in clinical practice (Figure 1).  
Non-SARS-CoV-2 sera (n=79) collected prior to the COVID-19 pandemic (between January 
2019 and December 2019) with potential cross-reactions (cross-reactivity test group) were also 
analyzed. Samples in this group included positive antinuclear antibodies (n=5), anti-
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(n=1), anti-thyroid peroxidase antibodies (n=4), chikungunya antibody (n=1), direct Coombs 
(n=1), hepatitis B Ag (n=4), hepatitis C antibodies (n=7), hepatitis E antibodies (n=4), human 
immunodeficiency virus antibodies (n=2), IgA Chlamydia pneumoniae (n=1), IgG Chlamydia 
trachomatis (n=1), IgG Coxiella burneti (n=2), IgM Borrelia (n=1), IgM Coxiella burneti 
(n=1), IgM cytomegalovirus (n=5), IgM Ebstein Barr virus viral capsid (n=5), IgM Mycoplasma 
pneumoniae (n=6), IgM parvovirus B19 (n=7), IgM Toxoplasma gondii (n=5), influenza 
antibodies (n=6), RAI (search for irregular agglutinins) (n=2), and rheumatoid factor (n=5). The 
calculated specificity was 100% (95%CI: 95.44-100.0%). Using the ROC curve cut-off 
(i.e.>0.165) had no effect on the measured diagnostic specificity (Figure 1). 
The optimal ROC cut-off showed excellent clinical performance 14 days or more following 
RT-PCR positivity or following the onset of COVID-19 symptoms. Additional studies are 
needed to further confirm the best cut-off. Expert societies are also urged to provide guidance 
on the best time after RT-PCR positivity or symptom onset to perform serological 
investigations, since this is an important determinant of the true positivity rate. 
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Figure legend 
Figure 1: Clinical performance of the Elecsys anti-SARS-CoV-2 assay subdivided by time 
since the RT-PCR positivity or since the onset of symptoms. Cross-reactivity refers to the cross-
reactivity test group described in the text. * = unaffected by the cut-off used (≥1.0 or >0.165). 
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